首页> 外文期刊>RSC Advances >The tetrameric peptide LfcinB (20-25)(4) derived from bovine lactoferricin induces apoptosis in the MCF-7 breast cancer cell line
【24h】

The tetrameric peptide LfcinB (20-25)(4) derived from bovine lactoferricin induces apoptosis in the MCF-7 breast cancer cell line

机译:衍生自牛乳铁蛋白的四聚肽LFCINB(20-25)(4)诱导MCF-7乳腺癌细胞系中的细胞凋亡

获取原文
获取原文并翻译 | 示例
           

摘要

The cytotoxic effect of the tetrameric peptide LfcinB (20-25)(4) against breast cancer cell line ATCC (R) HTB-22 (TM) (MCF-7) was evaluated. The tetrameric peptide exhibited a concentration-dependent cytotoxic effect against MCF-7 cancer cells. The peptide at 22 mu M had the maximum cytotoxic effect against MCF-7 cancer cells, reducing their cell viability to similar to 20%. The cytotoxic effect of the tetrameric peptide against MCF-7 cells was sustained for 24 hours. Furthermore, the tetrameric peptide did not exhibit a significant cytotoxic effect against the non-tumorogenic trophoblastic cell line, which confirms their selectivity for breast cancer cell lines. The MCF-7 cells treated at 12.2 mu M for 1 h exhibited morphological changes characteristic of apoptosis, such as rounded forms and cellular shrinkage. Furthermore, this peptide induces severe cellular damage to MCF-7 cells, mitochondrial membrane depolarization, and increase of cytoplasmic calcium concentration. Our results suggest that it has a significant selective cytotoxic effect against MCF-7 cells, which may be mainly associated with the apoptotic pathway. This peptide, which contains the RRWQWR motif, could be considered to be a promising candidate for developing therapeutic agents for the treatment of breast cancer.
机译:评价四聚肽LFCINB(20-25)(4)对乳腺癌细胞系ATCC(R)HTB-22(TM)(MCF-7)的细胞毒性作用。四聚体肽表现出对MCF-7癌细胞的浓度依赖性细胞毒性作用。肽在22 mu m处具有对MCF-7癌细胞的最大细胞毒性作用,降低它们的细胞活力与20%相似。四聚肽对MCF-7细胞的细胞毒性作用持续24小时。此外,四聚体肽对非致致致致致致胆细胞细胞系具有显着的细胞毒性作用,这证实了它们对乳腺癌细胞系的选择性。在12.2μmmm处处理的MCF-7细胞1小时表现出细胞凋亡的形态变化,例如圆形的形式和细胞收缩。此外,该肽对MCF-7细胞,线粒体膜去极化和细胞质钙浓度的增加诱导严重的细胞损伤。我们的研究结果表明,对MCF-7细胞具有显着的选择性细胞毒性作用,其可能主要与凋亡途径有关。含有RRWQWR基序的该肽可以被认为是用于培养治疗乳腺癌的治疗剂的有希望的候选者。

著录项

  • 来源
    《RSC Advances》 |2019年第36期|共8页
  • 作者单位

    Univ Nacl Colombia Pharm Dept Carrera 45 26-85 Bldg 450 Off 213 Bogota 11321 Colombia;

    Univ Nacl Colombia Chem Dept Carrera 45 26-85 Bldg 451 Off 409 Bogota 11321 Colombia;

    Univ Michoacana Fac Vet Med &

    Zootech Multidisciplinary Ctr Studies Biotechnol Km 9-5 Carretera Morelia Zinapecuaro Morelia Michoacan Mexico;

    Univ Michoacana Fac Vet Med &

    Zootech Multidisciplinary Ctr Studies Biotechnol Km 9-5 Carretera Morelia Zinapecuaro Morelia Michoacan Mexico;

    Univ Nacl Colombia Chem Dept Carrera 45 26-85 Bldg 451 Off 409 Bogota 11321 Colombia;

    Univ Nacl Colombia Chem Dept Carrera 45 26-85 Bldg 451 Off 409 Bogota 11321 Colombia;

    Univ Nacl Colombia Chem Dept Carrera 45 26-85 Bldg 451 Off 409 Bogota 11321 Colombia;

    Univ Nacl Colombia Pharm Dept Carrera 45 26-85 Bldg 450 Off 213 Bogota 11321 Colombia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号